Academic and Public Partnerships in Solid-State Chemistry - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Academic and Public Partnerships in Solid-State Chemistry
Solid-state chemistry is an important part of drug development, and public research is advancing the field.


Pharmaceutical Technology
Volume 37, Issue 5, pp. 56

Although the actual synthesis of an API is crucial, it is not the exclusive consideration in API development. In addition to producing an API with high purity, yield and stereoselectivity, an API must be able to remain stable during storage and distribution and have the desired drug mechanism once administered to a patient. Solid-state chemistry is an important part of drug development, and public research is advancing the field.

Researchers at the Institute of Chemical and Engineering Sciences (ICES) at Singapore's Agency for Science, Technology, and Research (A*STAR) recently reported on a novel method for producing cocrystals. The researchers discovered that adding water droplets can help form cocrystals of caffeine. Caffeine is unstable to humidity and cocrystal formation is possible with biocompatible compounds such as 4-hydroxybenzoic acid (4HBA). Previous research showed that computer models could predict cocrystals of caffeine and 4HBA in the ratio of 1:1, which would be the form with the most stable structure. To date, researchers had only been able to produce 2:1 and 1:2 co-crystals, according to information from A*STAR (1).

The ICES researchers successfully formed 1:1 cocrystals of caffeine and 4HBA in the form of a monohydrate. By grinding together a 1:1 mixture of the two components with two drops of water, a crystal structure was formed in which each pair of crystallization partners is partly held together by a water molecule. The key to the water's ability to produce the 1:1 cocrystal is its capacity to both donate and accept hydrogen bonds, the intermolecular force that holds cocrystals components together. In the case of the caffeine-4HBA cocrystal hydrate, unused hydrogen-bond acceptors and donors are satisfied by forming hydrogen bonds with the water molecule. Without water, the number of hydrogen-bond donors and acceptors is unbalanced, resulting in the preferential formation of the 2:1 and 1:2 crystals instead, according to the A-STAR information. The researchers have also applied the process to other APIs. They generated a 1:1 cocrystal hydrate of 4HBA with piracetam, a cognitive-enhancing drug. The results suggest that forming hydrates offers an alternative way to generate cocrystals with particular ratios of constituents, expanding the options for forming pharmaceutical materials.

The Synthesis & Solid State Pharmaceutical Center (SSPC) at the University of Limerick in Ireland was recently one of seven research centers that received part of an EUR 300 million ($391 million) investment through the Science Foundation Ireland's (SFI) Research Centers Program. SFI is the national research foundation in Ireland, and the funding represents funding from both SFI and private funding from industry. SSPC is a collaboration between 17 companies and academic institutions. These groups have expertise in process modelling and design, scale-up, computational fluid dynamics, in situ solution and solid-phase monitoring, crystallography and powder characterisation. The center's goal is to rationally design solid-state pharmaceutical materials in the required physical and chemical forms for advanced formulation and drug-delivery systems.

Reference

1. S. Aitipamula et al., Cryst. Eng. Comm. 14 (7), 2381–2385 (2012).

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here